Home
overview
New opportunities in the treatment of obesity highlight significant commercial opportunities for the pharmaceutical industry today. The potential for anti-obesity treatment is extensive with an estimated clinically obese population of over 250 million globally in the year 2003. As a rapidly growing global epidemic, obesity is also a major factor for co-morbidities such as type II diabetes, cardiac disorders and hypertension, which now account for over 60% of the 56.5 million deaths per year around the world that are deemed preventable.

SMi’s 2nd Annual Conference on Obesity & Related Disorders will endeavour to review and evaluate the causes of obesity and associated chronic diseases, with a focus on the current and future opportunities in the anti-obesity drug market, disease management and product pipelines. This conference will also assess the success of anti-obesity drugs already released onto the market, current drivers and shapers and the future opportunities and novel mechanisms available to fight obesity.

Furthermore, SMi's Obesity & Related Disorders Conference will discuss the latest in regulatory guidelines, assessing both implication and  implementation methods of achieving successful drug approvals.

A unique opportunity to learn from leading industry experts including:

  • Dr Terry Opgenorth, Divisional Vice President, Metabolic Disease Research, Abbott
  • Dr Tung Fong, Director, Metabolic Disorders, Merck
  • Dr Richard Carr, Scientific Director, Experimental Medicine, Novo Nordisk
  • Dr Monique Berwaer, Head, Metabolic Diseases, Johnson & Johnson
  • Dr Manfred Ganz, Specialist Internal Medicine, Diabetologist & Associate Professor, Clinical Management, University of Rome & Director & Head, Medical Assessment Strategy & Business Development, Roche Diagnostics
  • Dr Marcus Schindler, Associate Director & Group Leader, Metabolic Diseases, Boehringer-Ingelheim
  • Dr Cord Dohrmann, Chief Scientific Officer, DeveloGen
  • Dr Andrew Swick, Director, Cardiovascular & Metabolic Diseases, Pfizer
  • Dr Yehonatan Sharabi, Head, Hypertension Unit, C. Sheba Medical Center & Investigator, National Institute of Neurological Disorders & Stroke (NINDS), National Institutes of Health

The essential event on:

  • CURRENT AND FUTURE APPROACHES TO THE TREATMENT OF OBESITY: Discover the latest in target identification and validation, gut peptides, thermogenesis and the role of ghrelin in drug development
  • NEW DRUG DEVELOPMENTS: Hear about efficacy testing of anti-obesity drugs, novel inhibitory drugs and Sibutramine
  • OBESITY AND RELATED DISORDERS: Learn about new views on the progression from obesity to diabetes and the multifactorial and complex mechanisms of obesity-induced hypertension
  • GUIDANCE FOR REGULATORY APPROVAL: Understand the current FDA guidances and potential modifications for future drug approval
  • KEY INDUSTRY PERSONNEL: Meet the leaders in the field, learn from their experiences and make valuable contacts

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Cord Dohrmann

Cord Dohrmann, Chief Scientific Officer, DeveloGen AG

9:10 TARGET IDENTIFICATION AND VALIDATION

Tung Fong

Tung Fong, Director, Metabolic Disorders, Merck

  • Identifying the central targets for anti-obesity drugs - leptin vs others
  • Current and novel targets
  • Requirement of a successful drug for the treatment of obesity
  • Challenges, benefits and limitations of these targets
  • 9:50 EARLY STAGE DISCOVERY

    Monique Berwaer

    Monique Berwaer, Head, Metabolic Disease, Johnson & Johnson

  • Mechanisms and target choice
  • Most promising targets: overview
  • What about ghrelin?
  • 10:30 Morning Coffee

    11:00 GUT PEPTIDES

    Simon Luckman

    Simon Luckman, Pricipal Investigator & Senior Lecturer, University of Manchester

  • The gut can signal to the brain via nerves or hormones
  • Vagal nerve endings are sensitive to cholecystokinin, leptin and ghrelin
  • The hormone ghrelin can induce feeding
  • Systematically administered peptide YY can reduce food intake
  • It has been hypothesised that the gut signals hunger and  satiety to the brain
  • Controversies concerning the actions of these peptides will be discussed
  • 11:40 PANEL DISCUSSION

    Monique Berwaer

    Monique Berwaer, Head, Metabolic Disease, Johnson & Johnson

    Klaus Dembowsky

    Klaus Dembowsky, Vice President, Drug Discovery, Ingenium Pharmaceuticals

    Simon Luckman

    Simon Luckman, Pricipal Investigator & Senior Lecturer, University of Manchester

    12:50 Networking Lunch

    14:20 STIMULATION OF THERMOGENESIS AND OTHER INTERVENTIONS IN ENERGY METABOLISM

    Jon Arch

    Jon Arch, Professorial Research Fellow & Deputy Director, Metabolic Research, University of Buckingham

  • Why target metabolism?
  • Overview of physiological and biochemical mechanisms
  • Where and what are the targets?
  • Validation of metabolic targets
  • Expectations of thermogenic drugs
  • 15:00 SYSTEMIC APPROACH TO IDENTIFY NOVEL GENES RELEVANT FOR THE TREATMENT OF OBESITY

    Klaus Dembowsky

    Klaus Dembowsky, Vice President, Drug Discovery, Ingenium Pharmaceuticals

  • Phenotypic screening of mice treated with ENU for obesity relevant parameters
  • High throughput in vivo screen with ENU mutagenesis
  • Diseases vs therapy relevant genes for obesity
  • Results will be exemplified by the Chagall phenotype
  • Chagall mice have highly reduced adipose tissue and are  resistant to high fat diet in the absence of gross metabolic changes
  • This phenotype is caused by a point mutation in a novel transmembrane transporter
  • 16:00 OBESITY DRUGS

    Richard Atkinson

    Richard Atkinson, President, American Obesity Asscociation

  • Obesity as a chronic disease and extent of the problem
  • Rationale for use of obesity drugs, alone and in combination
  • Discrimination against obesity: effects on obesity drug approval and use
  • Characteristics and effectiveness of current obesity drugs
  • Categories of future agents to treat obesity
  • Elements of a successful clinical trial
  • Current FDA guidances and potential modifications for future drugs
  • Safety issues: balancing effectiveness and risks in using obesity drugs
  • 16:40 SEROTONIN NOREPINEPHRINE RE-UPTAKE INHIBITOR

    Terry Opgenorth

    Terry Opgenorth, Divisional Vice President, Metabolic Disease Resea, Abbott

  • Approval process
  • Beneficial effects of Sibutramine on metabolic syndrome parameters
  • Response in non-diabetic and diabetic patients
  • Efficacy in long-term obesity management
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Klaus Dembowsky

    Klaus Dembowsky, Vice President, Drug Discovery, Ingenium Pharmaceuticals

    9:10 GLOBAL MARKET OVERVIEW

    Manfred Ganz

    Manfred Ganz, Director & Head, Medical Assessment Strategy & Business Development, Global Diabetes Care, Roche Diagnostics

  • Understanding the aetiology and epidemiologyof the obesity crisis
  • The changing medical and popular perceptions of obesity
  • Classification and designation of obesity as a disease
  • Behaviour modification vs metabolic disorder: targeting school children and their families
  • Profile of the target market and their future medical needs
  • Obesity as underlying pathogenesis of diabetes and the metabolic syndrome
  • 9:50 IN VIVO EFFICACY TESTING OF ANTI-OBESITY

    Marcus Schindler

    Marcus Schindler, Associate Director & Group Leader, Metabolic Diseases, Boehringer-Ingelheim Pharma GmbH & CoKG

  • Diet induced obesity: rodent models (cafeteria diet, high-fat diet)
  • Examples of the use of non-rodent species
  • Sibutramine in Cynomolgus monkeys
  • Dexfenfluramine in Rhesus monkeys
  • Sibutramine in domestic pigs
  • 10:30 Morning Coffee

    11:00 ATL-962: A NOVEL GASTROINTESTINAL LIPASE INHIBITORY ANTI-OBESITY DRUG

    Richard Palmer

    Richard Palmer, Chief Executive Officer & Director, R & D, Alizyme

  • Pharmacodynamic studies
  • Initial Phase IIb efficacy data from obese patients
  • Positioning in anti-obesity pharmacotherapy
  • 11:40 INSULIN RESISTANCE AND ADIPOSE TISSUE

    Cord Dohrmann

    Cord Dohrmann, Chief Scientific Officer, DeveloGen AG

  • Insulin resistance and T2D
  • Adipose tissue as the primary site of insulin resistance?
  • Screening for targets involved in the regulation of fat metabolism
  • DG70 a novel kinase regulating insulin sensitivity
  • Development of DG70 inhibitors as insulin sensitisers
  • 12:20 Networking Lunch

    13:50 A DIET-INDUCED MARMOSET MODEL FOR OBESITY,

    Mark Paulik

    Mark Paulik, Group Leader, Metabolic Diseases, GlaxoSmithKline

  • Results will be presented on the development, validation and utility of a diet-induced obese Marmoset model that offers a predictive non-human primate model of obesity and metabolic syndrome
  • Marmosets placed on a high-fat diet for three months exhibited a 27% increase in body weight
  • Both body composition changes and serum chemistry modulations mirror those observed in obese humans
  • Marmosets treated with the anti-obesity agents Rimonabant or Sibutramine for four weeks, demonstrated analogous changes in weight and serum chemistries as those achieved in the clinic
  • In summary, diet-induced obese Marmosets are excellent models for the study of both obesity and metabolic syndrome that can ultimately be used to accelerate the development of pharmaceuticals to treat these rising epidemics
  • 14:30 PGC-1: INSULIN RESISTANCE

  • Does obesity and physical inactivity aggravate insulin resistance?
  • The symptoms of insulin resistance
  • Causes of insulin resistance
  • Treatment of insulin resistance
  • Richard Carr

    Richard Carr, Scientific Director, Experimental Medicine, Novo Nordisk

    Karin Rimvall

    Karin Rimvall, Senior Scientist, Department Head, Novo Nordisk

    15:10 Afternoon Tea

    15:40 COMMON METABOLIC DISEASES: OBESITY AND TYPE 2 DIABETES

    Andrew Eisen

    Andrew Eisen, Assistant Director & Head, Metabolic Disorders, CuraGen

  • Aspects of the metabolic syndrome
  • Understanding the physiological and biochemical factors underlying these metabolic disturbances
  • New genes, new pathways and new endocrinology
  • Discovering and validating potential new targets for obesity and diabetes
  • Current approaches and novel drug targets
  • Developing better therapeutic outcomes
  • 16:20 OBESITY-INDUCED HYPERTENSION

    Yehonatan Sharabi

    Yehonatan Sharabi, Head, Hypertension Unit, NIH

  • The prevalence of obesity-related hypertension
  • Adipocytokines and the pathogenesis of cardiovascular consequences of obesity
  • Systemic hemodynamics in obesity
  • Association of hyperinsulinema with obesity
  • Studies and figures
  • What this means for industry
  • Clinical strategies
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Jurys Great Russell Street Hotel

    16-22 Great Russell Street
    London WC1B 3NN
    United Kingdom

    Jurys Great Russell Street Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.